Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Cabiralizumab in Resectable Biliary Tract Cancer
NCT03768531Phase 2Withdrawn
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jun 2019
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of cabiralizumab in biliary tract cancer (BTC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Planned start Jun 2019; status: withdrawn.
02
Drugs
cabiralizumab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT03768531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03768531.